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Cardiovascular diseases, formerly only attributed to the alterations of the stromal component, are now recognized as immune-
based pathologies. Plasmacytoid Dendritic Cells (pDCs) are important immune orchestrators in heart and vessels. They highly
produce IFN type I that promote the polarization of T cells towards a Th1 phenotype; however, pDCs can also participate to
suppressive networks via the recruitment of T regulatory cells that downmodulate proinﬂammatory responses. pDCs populate the
vessel wall layers during pathological conditions, such as atherosclerosis. It is thus clear that a better identiﬁcation of pDCs activity
in cardiovascular diseases can not only elucidate pathological mechanisms but also lead to new therapeutic approaches.
1.Introduction
Cardiovascular diseases, formerly only attributed to the
alterations of the stromal component, are now recognized
as immune-based pathologies. [1]. Only in the late 1980s,
studies highlighted the link between the inﬂammatory
response and the immune system in cardiovascular diseases
[1, 2]. Indeed, inﬂammation is a component of many vas-
cular disorders such as aortic aneurysm, giant cell arteritis,
Takayasu’s Disease, Kawasaki Disease, and atherosclerosis
[1, 2].
The cardiovascular system can be compromised by
hemodynamic factors, such as the high blood pressure, by
the thickness of the aortic sinus and aorta [1, 2]. However,
the immune system contributes to the exacerbation of
cardiovascular pathologies, such as atherosclerosis, heart
failure, arteritis, and aortic aneurysm [1]. Any kind of
insult to the cardiovascular system can induce the release
of proinﬂammatory cytokines and chemokines and facilitate
the recruitment of immune cells, such as dendritic cells,
macrophages, and T cells, which promote the inﬂammation
with the release of a variety of inﬂammatory mediators
[1, 2]. In turn, the stromal cells, such as smooth muscle
cells and endothelial cells, also participate in this process
either by expanding the extracellular matrix or by releasing
other proinﬂammatory molecules. This tends to exacerbate




Dendritic cells (DCs) are professional Antigen Presenting
Cells (APCs), which process and present antigens to na¨ ıve
lymphocytes, B cells, Natural Killer (NK), and NKT cells
[3]. DCs are identiﬁed in two speciﬁc subsets, conventional
(cDCs) and plasmacytoid DCs (pDCs) [4, 5]. In contrast
to humans, mice are characterized by many diﬀerent DCs
subsets as determined by the cluster diﬀerentiation markers
[6].MouseDCsareidentiﬁedasCD11chigh CD11b
low butcan
also be discriminated by the expression of CD4+ CD8α+a n d
CD4-CD8α-[ 6, 7].
Human pDCs are CD4+ CD45RA+ IL-3αR (CD123)+
ILT3+ ILT1- CD11clow/− cells [6]. Two additional surface
markers on human pDCs are represented by BDCA-2
and BDCA-4, that correspond to the murine mPDCA-1,
restricted to the peripheral blood and bone marrow-derived
pDCs [6]. Mouse pDCs share most of the morphological
and phenotypical features with the human counterpart;
however, murine pDCs are distinguished as CD11clow/− Gr-
1+/intermediate B220+ 120G8+ cells [6, 7]. The recognition of
the cluster diﬀerentiation proteins is actually very important2 International Journal of Vascular Medicine
not only to distinguish pDCs from cDCs and other cell types
but also for the isolation of these cells.
Mouse pDCs have been identiﬁed in lymphoid organs
but also the liver, the lung, the heart, the vessels and
the skin although their proliferation rate is very low dur-
ing physiological conditions [7, 8]. Instead, human pDCs
populate primary, secondary and tertiary lymphoid organs
(aggregates/follicles), the liver and the blood [9]. During
pathological conditions, pDCs migrate from the bone mar-
row or the circulation to the damaged tissue through the
high endothelial venules [7] .C D 6 2 Le x p r e s s e do np D C s
ligate L-selectin ligands expressed on endothelial and other
stromal cells [6]. The repertoire of chemokine receptors on
pDCs is higher expressed than those on cDCs [6]. CXCR3,
highly expressed under interferon (IFN) γ production, binds
to CXCL19 and CXCL10 and is highly required by pDCs
to migrate into inﬂamed lymph nodes [10, 11]. Additional
chemokine receptors expressed by pDCs are CCR1, CCR2,
and CCR5 that bind to CCL2, CCL3, CCL4, and CCL5;
they express CXCR4, implicated in pDCs migration, and
CCR7 for the constitutive chemokines CXCL12 and CCL21
[10, 11].
The recognition of some pathogen-associated molecu-
lar patterns (PAMPs) and/or danger-associated molecular
patterns (DAMPs) by pDCs promotes their mobility into
the circulation up to the damaged tissue [12, 13]w h e r e a s
cDCs can also recognize the antigens into the tissue and
then present them into the lymphoid organs. One of the
functional consequences is that pDCs are not recognized as
APCs [13], as in the case of cDCs, but they can polarize
T cells towards a Th1 or immunosuppressive phenotype
[13, 14].
3.ActivationofPlasmacytoidDCs(pDCs)
pDCs are deﬁned as professional interferon- (IFN-) pro-
ducing cells (IPCs), a characteristic that depends on the
expression of some cytoplasmic receptors, such as TLRs, that
promptly detect DNA or RNA from viruses and bacteria
[14]. pDCs and cDCs have a diﬀerent repertoire of TLRs
expression. Human and mouse cDCs can express TLR1, 2,
3, 4, 5, 7, and 8 [15], while pDCs uniquely express TLR7 and
TLR9 in the endosomes [16], which sense nucleic acids [14].
Many studies have shown that the exposure of pDCs to TLR7
or TLR9 agonists (imiquimod and CpG-ODN, respectively)
can lead to the production of IFNα and proinﬂammatory
cytokines, such as TNFα and IL-8, essential to strengthen
pDC-mediated T cell stimulation [17]. Very importantly,
IFNα modulates several aspects of the immune system,
including pDCs survival, cDCs diﬀerentiation, modulation
of Th1 and CD8+ T cell responses, crosspresentation, upreg-
ulation of MHC and costimulatory molecules, activation of
NK cells, and induction of primary antibody responses [17].
pDCs activation can also lead to the production of IL-
12p70 [14, 17], IL-1β, and IL-6 [14]. Furthermore, it is of
very recent discovery that pDCs may mediate the release of
IL-10 [18]. However, an outstanding group proved that these
cells do not directly produce IL-10 [19].
4.pDCs AreBridging Cellsbetweenthe
InnateandtheAdaptiveImmunity
The production of IFN type I renders pDCs the bridge
between the innate and the adaptive immune system. IFNs
type I (IFNα and IFNβ) are released upon viral infections
[17] and also during some cardiovascular diseases, such
as atherosclerosis [20]. Upon activation, pDCs, rather than
cDCs, produce higher amounts of IFNα that, in turn,
ampliﬁes the production of the same cytokine or IL-12p70
from cDCs and NK cells [17, 21], ending with the activation
of the adaptive immune system. Thus, activated pDCs
can directly or indirectly induce T cell IFNγ production,
promote Th1 polarization [13, 14], and induce cytotoxic
T lymphocyte- (CTL-) mediated responses [13]a sw e l la s
proliferation and survival of T cells.
However, very recent studies demonstrate that pDCs
can also lead to the synthesis of a tolerogenic enzyme,
indoleamine-2, 3-dioxygenase (IDO) [22]. IDO is highly
present in human aortic smooth muscle cells and atheroma
[23], where it is associated to the tolerogenic inducible
costimulator ligand (ICOS-L), implicated in the regulatory
T cells network [23, 24]. To note, the increased synthesis
of IDO is associated to the autocrine eﬀect of IFN type I
on pDCs upon, for example, TLR9 activation and CD200R
ligands stimulation [14, 24]. Very interestingly, pDCs can
recruit T regulatory (Treg) cells through direct and indirect
interaction via the PD-L1/PD-1 axis [25, 26] and immuno-
suppressive cytokines, such as IL-10 [26].
It is obvious, then, that pDCs can have a dual role,
immunostimulant or immunosuppressive. A possible expla-
nation of this diﬀerence may simply be correlated to the
physiological negative feedback that occurs when an exces-
sive cytotoxic response can damage the host, or to the patho-
logical microenvironment. For example, the prostaglandin
E2 (PGE2), proinﬂammatory mediator highly relevant in
cardiovascular pathologies, can inhibit IFNα production and
the Th1 polarization induced by pDCs [27]. However, more
studies are needed in this regard to prove that PGE2 alters
pDCs activity during a cardiovascular disease.
Upon these ﬁndings, it seems very important that
the accumulation of pDCs into tissue may inﬂuence T
cell polarization and more importantly participate in the
resolution of the injury.
5.PlasmacytoidDendriticCells (pDCs) and
theirRole inCardiovascularDiseases
Two types of DCs, cDCs and pDCs, have been identiﬁed
in the atherosclerotic lesions, giant arteritis, and Kawasaki
Disease [1, 2, 28, 29]. DCs are present in the normal and
pathological intima [30, 31] and adventitia [32, 33]. This
strategical position allows DCs to be in a surveillance mode
to recognize antigens and then move to the draining lymph
nodes to ‘present’ to T cells.
Immature DCs (CD80/CD86 low-MHC II low) are
physiologically located in the adventitia and media of blood
vessels [28]; however, any type of insult, ranging fromInternational Journal of Vascular Medicine 3
pathogen-derived or host-derived, can facilitate the migra-
tion of DCs from the adventitia/media to the intima [28].
The interaction between DCs and endothelial cells can then
promote the recruitment of other immune cells [1, 2, 28].
The activation of the adaptive immune system may inﬂuence
the resolution of the injury or the prolonged immune
attack, which facilitates chronic inﬂammatory conditions,
deleterious for the cardiovascular system.
Very recent data from Weyand’s group indicate that
both cDCs and pDCs populate the human atherosclerotic
plaques[34,35].cDCsphysiologicallyresideintheadventitia
and media of the vessel wall [1, 2, 28]. The recognition
of antigens renders these wall-embedded cells essential for
a ﬁrst line of defence and surveillance. The migration of
cDCs to the lymphoid organs facilitates pDCs to migrate
towards the damaged tissues. In turn, pDCs can migrate to
the draining lymph nodes where they can polarize T cells
[12, 14].
pDCs are localized in the arterial and aortic sinus of
atheroscleroticplaquesinhumansandmice[20,33],concen-
trating into the unstable shoulder region of the plaques. The
production of IFN type I leads to a 10-fold increase of TNF-
relatedapoptosis-inducingligand(TRAIL)thatfacilitatesthe
apoptosis of vascular smooth muscle cells (VSMCs) laden
with oxysterols (plaque resident cells) [20]. On the other
hand, pDCs can modulate the generation/recruitment of
CD4+CD25+Foxp3+ Treg cell that play an important role in
the formation of atherosclerotic lesions in mice [36]. Treg
hamper the Th1 immunity, avoiding deleterious invasive
damages, but at the same time they impede the immune
system to combat the cardiovascular risk. Th1 responses can
be initiated by IFN type I whereas T regulatory pathways
are initiated by IL-10 and/or TGFβ [37]. pDCs release IFN
type I but can also promote the synthesis of IL-10 and
TGFβ via their regulatory patterns such as IDO and ICOSL
[23–25].
Similarly, excessive numbers of pDCs are observed in
the blood of heart failure patients [38]. A very interesting
paper has recently been reported showing that the deﬁciency
of Interleukin-1 receptor-associated kinase-4 (IRAK- 4),
downstream of MyD88-dependent TLRs signalling, avoids
the myocardial infarction [39]. This eﬀect is associated with
the reduction of CD11c positive inﬁltrating cells. cDCs and
pDCs are identiﬁed by this membrane integrin (CD11c).
Although the role of cDCs in this mouse model of infarct
is fundamental, it is also to note that pDCs may be as
well. IRAK4 is implicated in all MyD88-dependent TLRs
signalling, among which TLR7 and TLR9. It is not to exclude
thus that the activation of these receptors in pDCs could
be responsible for the myocardial infarction together with
cDCs. But, the potential role of pDCs in this pathology is far
from clear.
Another important ﬁnding is the localization of pDCs
in human and mouse Kawasaki Disease and giant arteritis
samples [28]. So far, it is still not known what is the
mechanism underlying the presence of pDCs in these
pathologies; however, pDCs correlate with the presence of
cDCs and T cells, leading to a possible functional role in the
coronaries, such as T cell polarization [28].
6. Conclusions andRemarks
pDCs are IFN-producing cells which could mediate a Th1-
like and T cytotoxic response; but also participate in the
immunosuppressive network.
Actually, there is no evidence that explains the vascular
presence of pDCs. However, we could speculate that pDCs
can be activated by circulating PAMPs and/or DAMPs,
which would promote their localization to the inﬂamed
locus such as in the case of the atherosclerotic plaques
[20, 33]. pDCs activation can then potentiate cDCs activity
[20] or alter adaptive immunity by inducing either Th1-like
immunityoranimmunesuppressiveadaptiveimmunity.The
microenvironment is essential to determine the capability
of pDCs to produce IFN type I. Thus, the identiﬁcation of
their role, and most of all, the connection between their
phenotype and the microenvironment may lead to new
potential therapeutic approaches for cardiovascular-related
pathologies.
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